Tejara Capital Ltd Reduces Stock Position in Mereo BioPharma Group plc (NASDAQ:MREO)

Tejara Capital Ltd decreased its position in shares of Mereo BioPharma Group plc (NASDAQ:MREO) by 18.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,317,085 shares of the company’s stock after selling 512,905 shares during the period. Mereo BioPharma Group makes up 5.2% of Tejara Capital Ltd’s holdings, making the stock its 5th biggest position. Tejara Capital Ltd owned 1.49% of Mereo BioPharma Group worth $8,110,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. State Street Corp bought a new position in Mereo BioPharma Group during the 3rd quarter worth $195,000. GSA Capital Partners LLP bought a new position in Mereo BioPharma Group during the 3rd quarter worth $276,000. Acuta Capital Partners LLC increased its position in Mereo BioPharma Group by 86.2% during the 3rd quarter. Acuta Capital Partners LLC now owns 1,260,700 shares of the company’s stock worth $5,181,000 after buying an additional 583,700 shares during the period. Janus Henderson Group PLC increased its position in Mereo BioPharma Group by 56.7% during the 3rd quarter. Janus Henderson Group PLC now owns 12,345,866 shares of the company’s stock worth $50,865,000 after buying an additional 4,464,984 shares during the period. Finally, Frazier Life Sciences Management L.P. increased its position in Mereo BioPharma Group by 15.8% during the 3rd quarter. Frazier Life Sciences Management L.P. now owns 5,097,779 shares of the company’s stock worth $20,952,000 after buying an additional 696,408 shares during the period. Institutional investors own 62.83% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Cantor Fitzgerald upgraded Mereo BioPharma Group to a “strong-buy” rating in a research report on Sunday, December 8th. Jefferies Financial Group started coverage on Mereo BioPharma Group in a research report on Friday, December 6th. They set a “buy” rating and a $7.00 price objective on the stock. Needham & Company LLC reissued a “buy” rating and set a $7.00 target price on shares of Mereo BioPharma Group in a report on Monday, January 13th. Finally, Lifesci Capital started coverage on Mereo BioPharma Group in a report on Tuesday, December 24th. They set an “outperform” rating and a $10.00 target price on the stock. Four research analysts have rated the stock with a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $7.83.

Mereo BioPharma Group Price Performance

MREO opened at $2.63 on Tuesday. The business’s fifty day moving average is $2.88 and its 200-day moving average is $3.61. Mereo BioPharma Group plc has a 52-week low of $2.25 and a 52-week high of $5.02.

Mereo BioPharma Group Profile

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.